KR100460583B1 - 간세포 암의 예방 및 치료 방법 - Google Patents
간세포 암의 예방 및 치료 방법 Download PDFInfo
- Publication number
- KR100460583B1 KR100460583B1 KR10-1999-7008375A KR19997008375A KR100460583B1 KR 100460583 B1 KR100460583 B1 KR 100460583B1 KR 19997008375 A KR19997008375 A KR 19997008375A KR 100460583 B1 KR100460583 B1 KR 100460583B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- residues
- cells
- peptide
- alphafetoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title description 10
- 230000002265 prevention Effects 0.000 title description 2
- 208000014018 liver neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims abstract description 49
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 25
- 230000028993 immune response Effects 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 98
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 22
- 210000004443 dendritic cell Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 31
- 150000001413 amino acids Chemical class 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 10
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 42
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 33
- 241001529936 Murinae Species 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 26
- 238000011081 inoculation Methods 0.000 description 20
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 15
- 102000046101 human AFP Human genes 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 201000008808 Fibrosarcoma Diseases 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 8
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 101100012845 Mus musculus Afp gene Proteins 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000011735 C3H mouse Methods 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 3
- 101100055006 Yersinia ruckeri serotype O1 (strain ATCC 29473 / DSM 18506 / JCM 15110 / NCIMB 2194 / NCTC 12986 / 2396-61) afp18 gene Proteins 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 101150094949 APRT gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3837597P | 1997-02-13 | 1997-02-13 | |
| US60/038,375 | 1997-02-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000071226A KR20000071226A (ko) | 2000-11-25 |
| KR100460583B1 true KR100460583B1 (ko) | 2004-12-08 |
Family
ID=21899585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-1999-7008375A Expired - Lifetime KR100460583B1 (ko) | 1997-02-13 | 1998-02-13 | 간세포 암의 예방 및 치료 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20020031520A1 (enExample) |
| EP (1) | EP0979239B1 (enExample) |
| JP (3) | JP3816959B2 (enExample) |
| KR (1) | KR100460583B1 (enExample) |
| CN (2) | CN1739791A (enExample) |
| AU (1) | AU6435398A (enExample) |
| DE (1) | DE69836209D1 (enExample) |
| WO (1) | WO1998035981A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100482920B1 (ko) * | 2000-02-10 | 2005-04-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 간세포암을 치료하기 위한 조성물 |
| FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
| US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
| GB0617564D0 (en) * | 2006-09-06 | 2006-10-18 | Ucl Business Plc | Peptides and methods |
| KR100900742B1 (ko) * | 2007-05-17 | 2009-06-08 | 크레아젠 주식회사 | 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법 |
| WO2011048503A2 (en) * | 2009-10-22 | 2011-04-28 | Moro Ricardo J | Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof |
| SG11201504558TA (en) | 2012-12-11 | 2015-07-30 | Einstein Coll Med | Methods for high throughput receptor:ligand identification |
| CN114456272A (zh) | 2015-04-03 | 2022-05-10 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
| CN105126074A (zh) * | 2015-09-30 | 2015-12-09 | 中国药科大学 | 多肽afp12在制备抗肿瘤药物中的应用 |
| CN105524884A (zh) * | 2016-02-29 | 2016-04-27 | 时宏珍 | Hla-a0201限制性抗afp抗原特异性ctl的制备方法 |
| SG11201808552XA (en) | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH025866A (ja) * | 1988-06-27 | 1990-01-10 | Kansai Shin Gijutsu Kenkyusho:Kk | ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ |
| IT1226551B (it) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| AU700975B2 (en) * | 1995-01-24 | 1999-01-14 | Merrimack Pharmaceuticals, Inc. | Recombinant human alpha-fetoprotein and uses thereof |
-
1998
- 1998-02-13 JP JP53591698A patent/JP3816959B2/ja not_active Expired - Lifetime
- 1998-02-13 CN CNA2005100915162A patent/CN1739791A/zh active Pending
- 1998-02-13 AU AU64353/98A patent/AU6435398A/en not_active Abandoned
- 1998-02-13 WO PCT/US1998/002753 patent/WO1998035981A1/en not_active Ceased
- 1998-02-13 CN CNB988052288A patent/CN1222536C/zh not_active Expired - Lifetime
- 1998-02-13 KR KR10-1999-7008375A patent/KR100460583B1/ko not_active Expired - Lifetime
- 1998-02-13 DE DE69836209T patent/DE69836209D1/de not_active Expired - Lifetime
- 1998-02-13 EP EP98910001A patent/EP0979239B1/en not_active Expired - Lifetime
-
1999
- 1999-08-12 US US09/373,913 patent/US20020031520A1/en not_active Abandoned
-
2006
- 2006-02-15 JP JP2006038626A patent/JP2006188528A/ja not_active Withdrawn
-
2010
- 2010-06-30 JP JP2010150627A patent/JP2010222379A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001515347A (ja) | 2001-09-18 |
| EP0979239A4 (en) | 2002-09-18 |
| CN1739791A (zh) | 2006-03-01 |
| DE69836209D1 (de) | 2006-11-30 |
| AU6435398A (en) | 1998-09-08 |
| CN1259139A (zh) | 2000-07-05 |
| US20020031520A1 (en) | 2002-03-14 |
| WO1998035981A1 (en) | 1998-08-20 |
| EP0979239A1 (en) | 2000-02-16 |
| JP2010222379A (ja) | 2010-10-07 |
| EP0979239B1 (en) | 2006-10-18 |
| CN1222536C (zh) | 2005-10-12 |
| JP3816959B2 (ja) | 2006-08-30 |
| JP2006188528A (ja) | 2006-07-20 |
| KR20000071226A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010222379A (ja) | 肝細胞癌の予防又は処置のための組成物 | |
| EP2280031B1 (en) | Cancer antigens based on products of the tumor suppressor gene WT1 | |
| KR100653590B1 (ko) | 시클로필린 ｂ 유래의 종양 항원 펩티드 | |
| JP4904384B2 (ja) | 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド | |
| JPWO2002010369A1 (ja) | 腫瘍抗原 | |
| JP5114403B2 (ja) | Ｈｌａ−ａ３スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なｓａｒｔ３由来ペプチド | |
| KR20060003903A (ko) | 사람 암배아 항원을 암호화하는 합성 유전자 및 이의 용도 | |
| KR100482920B1 (ko) | 간세포암을 치료하기 위한 조성물 | |
| KR20010080661A (ko) | 신규의 종양 항원 단백질 ａｒｔ-1 및 이의 종양 항원펩티드 | |
| EP1103561B1 (en) | Hla-a2 restraint tumor antigen peptide originating in sart-1 | |
| JP4925033B2 (ja) | ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド | |
| KR20110128008A (ko) | Ｒｎａ 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법 | |
| BECKER et al. | WORKSHOP 0 Tumor Immunology | |
| BENGA et al. | Workshop Q Tumor Immunology | |
| HK1037672A (en) | Novel tumor antigen protein sart-3 and tumor antigen peptide thereof | |
| HK1153761B (en) | Cancer antigens based on products of the tumor suppressor gene wt1 | |
| HK1034980A (en) | Tumor antigen peptide derivatives | |
| HK1130069B (en) | Tumor antigen based on products of the tumor suppressor gene wt1 | |
| HK1036996A (en) | Hla-a2 restraint tumor antigen peptide originating in sart-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19990813 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20010612 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031128 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20040903 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20041130 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20041201 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20071126 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20081124 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20091120 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101111 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111109 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20121107 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121107 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20131108 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131108 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141107 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20151109 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151109 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20161111 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161111 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20171110 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171110 Start annual number: 14 End annual number: 14 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20180813 Termination category: Expiration of duration |